Oxford Biomedica's Parkinson's licensee pulls out
1st Feb 2022 07:40
(Sharecast News) - Oxford Biomedica's licensee for a Parkinson's disease treatment has pulled out of development and returned the rights to the UK company.
Read moreOxford Biomedica creates venture with Homology, launches £80m fundraise
28th Jan 2022 09:56
(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.
Read moreOxford Biomedica CEO John Dawson to step down
17th Jan 2022 07:10
(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Read moreOxford Biomedica signs licence, supply deal with Cabaletta Bio
5th Jan 2022 07:29
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
Read moreOxford Biomedica strikes new license and supply agreements
13th Dec 2021 07:31
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Read moreBoehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology
19th Oct 2021 09:18
(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.
Read moreOxford Biomedica swings to profit on Covid-19 vaccine sales
22nd Sep 2021 07:03
(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read moreOxford Biomedica swings to profit on Covid-19 vaccine sales
22nd Sep 2021 07:03
(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
Read moreOxford Biomedica ups revenue forecast as AstraZeneca lifts vaccine output
18th May 2021 08:13
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Tuesday doubled annual earnings guidance after pharmaceutical giant AstraZeneca ordered more Covid-19 vaccines.
Read moreOxford Biomedica swings to EBITDA profit
15th Apr 2021 09:02
(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.
Read moreOxford Biomedica strikes three-year deal with Boehringer Ingelheim
6th Apr 2021 08:08
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.
Read moreOxford Biomedica says Sanofi pulling out of haemophilia project
19th Mar 2021 07:50
(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
Read moreOxford Biomedica strikes collaboration agreement with PhoreMost
9th Nov 2020 09:16
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.
Read moreOxford Biomedica partner delays Parkinson's disease treatment trial
30th Oct 2020 08:47
(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.
Read moreOxford Biomedica new manufacturing suite approved
6th Oct 2020 07:03
(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
Read more